NICM
PTLA

Neo Ivy Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Neo Ivy Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,633
Closed -$687K – 431
2019
Q3 		$687K Buy
+23,633
New +$663K 0.45% 82
2019
Q2 		– Sell
-18,365
Closed -$637K – 450
2019
Q1 		$637K Buy
+18,365
New +$530K 0.36% 131

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Neo Ivy Capital Management's PTLA Position: Q4 2019 in Review

Neo Ivy Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 23,633 shares — an estimated $687K sold.

Neo Ivy Capital Management first reported a position in PTLA in Q1 2019 and held it in 2 quarters. The position peaked at $687K in Q3 2019. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

  • Neo Ivy Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Neo Ivy Capital Management sold 23,633 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $687K.
  • Neo Ivy Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
  • Neo Ivy Capital Management's Portola Pharmaceuticals, Inc. position peaked at $687K in Q3 2019.
  • 224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on Neo Ivy Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.